Minimally Invasive Treatment of Atrial Fibrillation



Minimally Invasive Treatment of Atrial Fibrillation


Gorav Ailawadi



INTRODUCTION

Atrial fibrillation (AF) develops in nearly 5% of patients in their lifetime and is the most common arrhythmia. An estimated 5 million Americans suffer from AF, and this number is expected to triple by 2050. AF is associated with an increased risk of stroke, thromboembolism, and death. Moreover, AF is an underdiagnosed cause for tachycardia-induced cardiomyopathy. AF is responsible for nearly 26 billion dollars annually. For these clinical and economic reasons, there is great interest in developing effective treatments for AF.

Medical therapy is the first-line therapy for patients with AF but has been shown to have poor success at rhythm restoration. The advent of surgical and ultimately catheterbased ablation technologies has revolutionized approach for this devastating disease.

AF is now classified by the terms paroxysmal, persistent, and long-standing persistent according to the ACC/AHA guidelines. Paroxysmal is characterized by recurrent episodes that last <7 days or convert to sinus without cardioversion. Persistent AF refers to AF that lasts more than 7 days, while long-standing persistent AF is AF lasting more than 1 year. The terms intermittent, chronic, and permanent AF are no longer in use.

The Cox-Maze III procedure (so-called “Cut and Sew Maze”) became the gold standard for the cure of AF. Although this procedure has excellent long-term results, it was limited in its adoption due to patient morbidity and complexity for the surgeon. Within the last several years, a number of alternate energy sources were developed to create lesion sets to treat AF, which is a variant of the Cox-Maze III, often termed Cox-Maze IV.


PATHOPHYSIOLOGY OF ATRIAL FIBRILLATION

AF is characterized by macro reentrant electrical circuits in both atria. Each patient’s electrical circuitry is unique; thus, mapping AF in any given patient can be laborious and challenging. Endocardial mapping has demonstrated that the pulmonary veins and posterior left atrium are the critical anatomic targets for ablation in patients with isolated AF as well as those with concomitant valvular heart disease. Specifically, in patients with paroxysmal AF, the source for reentrant circuit appears to be from the pulmonary veins while in patients with persistent AF, regular and repetitive activation can be identified in the posterior left atrium, the pulmonary veins, and/or the left atrial appendage (LAA). Although routine intraoperative mapping is currently not feasible for guiding intraoperative AF ablation, an anatomic approach based on our understanding of pathophysiology and on empiric results is reasonable. In fact, such an anatomic (rather than map-guided) approach is rapidly becoming the standard for catheter-based ablation of AF. The Cox-Maze III and IV use predetermined lesions/incisions in anatomic locations to interrupt these circuits. Surgical intervention typically includes excision/ligation of the LAA, which may reduce the risk of recurrent AF, thromboembolism, and stroke.


Jun 15, 2016 | Posted by in CARDIAC SURGERY | Comments Off on Minimally Invasive Treatment of Atrial Fibrillation

Full access? Get Clinical Tree

Get Clinical Tree app for offline access